Nedkova-Hristova, Velina
Donadeu, Laura
Baliellas, Carmen
González-Costello, José
Lladó, Laura
González-Vilatarsana, Emma
Vélez-Santamaría, Valentina
de la Prida, Miosés Morales
Bestard, Oriol
Casasnovas, Carlos http://orcid.org/0000-0003-1170-2676
Funding for this research was provided by:
Pfizer (ID#63238211)
Article History
Received: 3 March 2024
Accepted: 8 April 2024
First Online: 10 May 2024
Declarations
:
: Laura Doneu’s funding: Predoctoral Contract for Health Research Training (PFIS) funded by Instituto de Salud Carlos III. Oriol Bestard´s funding: Competitive grant PI19/01710 funded by Instituto de Salud Carlos III and co-fundede by European Union (ERDF/ESF)—A way to build Europe. RICORS (Redes de Investigación Cooperativa Orientadas a Resultados en Salud) consortia (Intituto de Salud Carlos III).Competitive grant PI22/01019 funded by Instituto de Salud Carlos III and co-fundede by European Union (ERDF/ESF)—A way to build Europe. Carmen Baliellas, José González-Costello, Laura Lladó and Emma González-Vilatarsana has nothing to disclose.
: This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. Ethical approval was obtained by Ethics Committee for Drug Research of Bellvitge University Hospital and the Spanish Agency of Medicines and Medical Devices (reference number: EPA 020/20; CCP-TAF-2020-01). All methods were performed in accordance with the relevant guidelines and regulations. Written informed consent was obtained from all participants in the study for data collection.